Published in Antimicrob Agents Chemother on August 01, 2011
Ferrous iron-dependent delivery of therapeutic agents to the malaria parasite. Future Med Chem (2012) 0.83
Novel endoperoxide-based transmission-blocking antimalarials with liver- and blood-schizontocidal activities. ACS Med Chem Lett (2013) 0.79
Are Antimalarial Hybrid Molecules a Close Reality or a Distant Dream? Antimicrob Agents Chemother (2017) 0.75
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (2001) 36.00
Vivax malaria: neglected and not benign. Am J Trop Med Hyg (2007) 10.16
Primaquine therapy for malaria. Clin Infect Dis (2004) 4.66
Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg (2007) 4.58
Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci (1999) 4.52
Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nat Med (2007) 4.22
New medicines to improve control and contribute to the eradication of malaria. Nat Rev Drug Discov (2009) 4.00
A research agenda for malaria eradication: drugs. PLoS Med (2011) 3.90
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis (2010) 3.08
The silent path to thousands of merozoites: the Plasmodium liver stage. Nat Rev Microbiol (2006) 2.83
Primaquine revisited six decades after its discovery. Eur J Med Chem (2008) 2.43
Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging. PLoS One (2009) 2.18
Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS One (2007) 2.17
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrob Agents Chemother (2010) 2.15
Pharmacokinetics of artemisinin-type compounds. Clin Pharmacokinet (2000) 1.78
Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery. PLoS One (2011) 1.60
Dissecting in vitro host cell infection by Plasmodium sporozoites using flow cytometry. Cell Microbiol (2007) 1.50
Host scavenger receptor SR-BI plays a dual role in the establishment of malaria parasite liver infection. Cell Host Microbe (2008) 1.50
Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database Syst Rev (2007) 1.29
Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high stability and efficacy. J Med Chem (2003) 1.25
Kinome-wide RNAi screen implicates at least 5 host hepatocyte kinases in Plasmodium sporozoite infection. PLoS Pathog (2008) 1.20
Antimalarial drug synergism and antagonism: mechanistic and clinical significance. FEMS Microbiol Lett (2005) 1.14
A novel artemisinin-quinine hybrid with potent antimalarial activity. Bioorg Med Chem Lett (2007) 1.10
Establishment of an in vitro assay for assessing the effects of drugs on the liver stages of Plasmodium vivax malaria. PLoS One (2010) 1.08
Falcipain inhibitors: optimization studies of the 2-pyrimidinecarbonitrile lead series. J Med Chem (2010) 1.06
Design, synthesis and antimalarial activity of trifluoromethylartemisinin-mefloquine dual molecules. Chembiochem (2005) 1.03
Hybrid drugs for malaria. Curr Pharm Des (2009) 1.00
Vivax malaria: preliminary observations following a shorter course of treatment with artesunate plus primaquine. Trans R Soc Trop Med Hyg (2007) 0.92
The evolution of tafenoquine--antimalarial for a new millennium? J R Soc Med (1999) 0.91
Orally active, hydrolytically stable, semisynthetic, antimalarial trioxanes in the artemisinin family. J Med Chem (1999) 0.90
High antiplasmodial activity of novel plasmepsins I and II inhibitors. J Med Chem (2006) 0.89
Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin. J Med Chem (2003) 0.87
Artemisinin-dipeptidyl vinyl sulfone hybrid molecules: design, synthesis and preliminary SAR for antiplasmodial activity and falcipain-2 inhibition. Bioorg Med Chem Lett (2009) 0.81
Mechanism-based design of parasite-targeted artemisinin derivatives: synthesis and antimalarial activity of new diamine containing analogues. J Med Chem (2002) 0.81
Plasmepsin II inhibition and antiplasmodial activity of Primaquine-Statine 'double-drugs'. Bioorg Med Chem Lett (2004) 0.80
Identification of a dual histamine H1/H3 receptor ligand based on the H1 antagonist chlorpheniramine. Bioorg Med Chem Lett (2003) 0.78
A new class of ibuprofen derivatives with reduced gastrotoxicity. J Med Chem (2001) 0.78
Design and synthesis of new potent, silent 5-HT1A antagonists by covalent coupling of aminopropanol derivatives with selective serotonin reuptake inhibitors. Bioorg Med Chem Lett (1998) 0.77
Chemical genetics of Plasmodium falciparum. Nature (2010) 5.52
Rapid diagnostic tests for malaria at sites of varying transmission intensity in Uganda. J Infect Dis (2008) 4.60
Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nat Med (2007) 4.22
Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov (2004) 3.90
Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet (2002) 3.78
Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg (2003) 3.71
Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA (2007) 3.62
Home management of malaria with artemether-lumefantrine compared with standard care in urban Ugandan children: a randomised controlled trial. Lancet (2009) 3.21
Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial. Lancet (2004) 3.12
Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet (2007) 2.99
Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci U S A (2011) 2.94
Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ (2009) 2.84
The silent path to thousands of merozoites: the Plasmodium liver stage. Nat Rev Microbiol (2006) 2.83
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One (2008) 2.78
Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother (2006) 2.74
Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials (2006) 2.72
Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is unlinked to sequestration. Proc Natl Acad Sci U S A (2005) 2.71
Short report: proximity to mosquito breeding sites as a risk factor for clinical malaria episodes in an urban cohort of Ugandan children. Am J Trop Med Hyg (2003) 2.68
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials (2007) 2.63
Host-mediated regulation of superinfection in malaria. Nat Med (2011) 2.57
Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Lett (2003) 2.54
Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis (2005) 2.51
Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc Natl Acad Sci U S A (2005) 2.49
Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts. Acta Trop (2011) 2.46
Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis (2007) 2.44
Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. Am J Trop Med Hyg (2006) 2.43
Primaquine revisited six decades after its discovery. Eur J Med Chem (2008) 2.43
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis (2009) 2.42
Apoptotic Plasmodium-infected hepatocytes provide antigens to liver dendritic cells. J Infect Dis (2005) 2.42
Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum. Proc Natl Acad Sci U S A (2004) 2.33
Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Med (2005) 2.33
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J (2007) 2.30
Comparison of HRP2- and pLDH-based rapid diagnostic tests for malaria with longitudinal follow-up in Kampala, Uganda. Am J Trop Med Hyg (2007) 2.30
Factors determining the heterogeneity of malaria incidence in children in Kampala, Uganda. J Infect Dis (2008) 2.28
Yeast Ataxin-7 links histone deubiquitination with gene gating and mRNA export. Nat Cell Biol (2008) 2.27
High-resolution statistical mapping reveals gene territories in live yeast. Nat Methods (2008) 2.24
Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging. PLoS One (2009) 2.18
Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob Agents Chemother (2007) 2.12
High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis (2008) 2.05
Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother (2005) 2.00
Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. J Infect Dis (2011) 1.98
Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts. Clin Infect Dis (2012) 1.97
Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Am J Trop Med Hyg (2003) 1.96
A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. Cell Host Microbe (2013) 1.95
Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother (2006) 1.95
Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. J Infect Dis (2011) 1.94
Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. J Infect Dis (2006) 1.93
A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes. PLoS One (2008) 1.92
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother (2010) 1.83
Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr (2009) 1.83
Telomere tethering at the nuclear periphery is essential for efficient DNA double strand break repair in subtelomeric region. J Cell Biol (2006) 1.81
Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS (2007) 1.79
Gene disruptions demonstrate independent roles for the four falcipain cysteine proteases of Plasmodium falciparum. Mol Biochem Parasitol (2006) 1.78
Malaria blood stage suppression of liver stage immunity by dendritic cells. J Exp Med (2003) 1.78
Impact of transmission intensity on the accuracy of genotyping to distinguish recrudescence from new infection in antimalarial clinical trials. Antimicrob Agents Chemother (2007) 1.75
Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J (2011) 1.73
The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995-2005. Malar J (2006) 1.73
Increasing incidence of malaria in children despite insecticide-treated bed nets and prompt anti-malarial therapy in Tororo, Uganda. Malar J (2012) 1.65
Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso. Am J Trop Med Hyg (2006) 1.64
Heme oxygenase-1 is an anti-inflammatory host factor that promotes murine plasmodium liver infection. Cell Host Microbe (2008) 1.62
Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. Am J Trop Med Hyg (2003) 1.59
Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy. Am J Trop Med Hyg (2005) 1.59
Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda. Am J Trop Med Hyg (2004) 1.58
Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med (2012) 1.58
Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop Med Int Health (2004) 1.56
Sulfadoxine-pyrimethamine plus chloroquine or amodiaquine for uncomplicated falciparum malaria: a randomized, multisite trial to guide national policy in Uganda. Am J Trop Med Hyg (2005) 1.53
Host cell transcriptional profiling during malaria liver stage infection reveals a coordinated and sequential set of biological events. BMC Genomics (2009) 1.52
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother (2009) 1.52
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg (2014) 1.51
Discordant patterns of genetic variation at two chloroquine resistance loci in worldwide populations of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother (2008) 1.50
Dissecting in vitro host cell infection by Plasmodium sporozoites using flow cytometry. Cell Microbiol (2007) 1.50
Host scavenger receptor SR-BI plays a dual role in the establishment of malaria parasite liver infection. Cell Host Microbe (2008) 1.50
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother (2010) 1.49
Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi. J Med Chem (2004) 1.49
Accumulation of Plasmodium berghei-infected red blood cells in the brain is crucial for the development of cerebral malaria in mice. Infect Immun (2010) 1.47
Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis. Am J Trop Med Hyg (2011) 1.44
Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Clin Infect Dis (2014) 1.44
Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda. Antimicrob Agents Chemother (2007) 1.44
Use of the slide positivity rate to estimate changes in malaria incidence in a cohort of Ugandan children. Malar J (2009) 1.43
Plasmodium food vacuole plasmepsins are activated by falcipains. J Biol Chem (2008) 1.43
Impact of the method of G6PD deficiency assessment on genetic association studies of malaria susceptibility. PLoS One (2009) 1.43
Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children. PLoS One (2010) 1.42
The inner nuclear membrane protein Src1 associates with subtelomeric genes and alters their regulated gene expression. J Cell Biol (2008) 1.40
Apicoplast translation, transcription and genome replication: targets for antimalarial antibiotics. Trends Parasitol (2008) 1.39
Structure-activity relationships for inhibition of cysteine protease activity and development of Plasmodium falciparum by peptidyl vinyl sulfones. Antimicrob Agents Chemother (2003) 1.39
The seroprevalence of Helicobacter pylori and its relationship to malaria in Ugandan children. Trans R Soc Trop Med Hyg (2011) 1.39
Hepatocyte growth factor and its receptor are required for malaria infection. Nat Med (2003) 1.37
The relevance of non-human primate and rodent malaria models for humans. Malar J (2011) 1.36
Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. Malar J (2010) 1.34
False-positive results of enzyme immunoassays for human immunodeficiency virus in patients with uncomplicated malaria. J Clin Microbiol (2006) 1.34
Plasmodium falciparum cysteine protease falcipain-1 is not essential in erythrocytic stage malaria parasites. Proc Natl Acad Sci U S A (2004) 1.34